DGX — Quest Diagnostics Incorporated
Is DGX overbought or oversold? Here is the current MarketMoodz read.
Quest Diagnostics Incorporated (DGX) currently reads Neutral on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Diagnostics & Research) last closed at $256.54. The rating moved from Overbought to Neutral on November 12, 2026.
- Public ratingNeutral (as of November 17, 2026)
- Last close$256.54
- Last changeMoved from Overbought to Neutral on November 12, 2026
- SectorHealthcare
- IndustryDiagnostics & Research
AI analysis
Quest Diagnostics is a cash‑generative, large‑scale clinical laboratory operator with durable demand from chronic care and an aging patient base. Scale and a broad test menu support competitive positioning and margin resilience, while specialty/esoteric testing and service relationships with biopharma distributors offer incremental growth channels. Near‑term earnings are sensitive to payor reimbursement trends and regulatory tightening around Medicare/Medicare Advantage program integrity, which could elevate compliance costs or claw back overpayments. Absent material new catalysts, expect consolidation-like trading with moderate upside if specialty testing growth and cost initiatives offset reimbursement headwinds.
Key factors
- Steady, recession‑resilient demand for diagnostic testing driven by chronic disease management and an aging population
- Large national lab network and scale advantages that support pricing negotiations and operational efficiency
- Diversified revenue mix including routine testing, anatomic pathology, and growing specialty and esoteric testing services
- Consistent free cash flow generation and a history of shareholder returns (dividends and buybacks) supporting capital allocation flexibility
- Exposure to payor dynamics and Medicare reimbursement trends that create earnings sensitivity to policy and contract changes
- Potential incremental revenue from specialty care, infusion and biopharma services as distribution and prescription flows shift
Risks
- Medicare/Medicaid reimbursement cuts or increased RADV/claims clawbacks that reduce realized revenue and margins
- Commercial payor pricing pressure and aggressive network negotiations that compress reimbursement rates
- Competition from hospital systems, regional labs, and emerging diagnostics/at‑home testing providers
- Regulatory or compliance costs rising due to tighter program integrity measures (increasing SG&A and verification overhead)
- Decline in high‑margin pandemic‑related volumes or one‑time testing spikes that previously boosted results
- Execution risk on cost programs, integration of acquisitions, and maintaining throughput without quality lapses
See today's live rating, score and targets
Members see the live hourly rating for DGX — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.